EpiCast Report: Chronic Hepatitis B – Epidemiology Forecast to 2024
The Hepatitis B Virus (HBV) can cause both acute and chronic liver disease. HBV is typically transmitted through contact with infectious blood or bodily fluid, including vertical transmission from mother to child at birth and transmission via sexual intercourse. Risk factors of chronic hepatitis B (CHB) include unprotected sex with an infected partner, men who have sex with men (MSM), intravenous drug injection (IDU), and a previous history of a sexually transmitted disease (STD). CHB has a well-established comorbidity association with hepatitis C virus (HCV) infection, hepatitis D virus (HDV) infection, human immunodeficiency virus (HIV) infection, and alcohol abuse. The disease often starts as asymptomatic in the acute infection phase, with symptoms beginning to present 30 to 180 days from infection. When symptoms develop, they present as nausea, vomiting, loss of appetite, flu-like symptoms, and jaundice. Severe cases of HBV infection increase the risk of developing liver cancer and cirrhosis.
MRS epidemiologists forecast an increase in the diagnosed prevalent cases of chronic hepatitis B (CHB) in the 8MM, from 10,557,407 cases in 2014 to 10,861,653 cases in 2024, at an Annual Growth Rate (AGR) of 0.29% in the forecast period. The distribution of diagnosed prevalent chronic hepatitis B cases in the 8MM was greater in men (7,379,948 cases, 69.90% in 2014) than in women (3,177,459 cases, 30.10% in 2014). This skew towards men was found to be consistent across all markets.
MRS epidemiological forecast for the diagnosed prevalent cases of CHB are supported by age- and sex-specific data obtained from country-specific studies published in peer-reviewed journals, in which the study populations are representative of the general population in the respective markets. The diagnosed prevalent cases are further segmented into ALT level, HBV DNA level, HBeAg status, cirrhosis status, and co-infection with hepatitis C and HIV, thus providing a comprehensive view of the characteristics of CHB patients in the 8MM. Additionally, MRS epidemiologists used the same methodology across the 8MM, which allows for a meaningful comparison of the forecast diagnosed incident cases and diagnosed prevalent cases of CHB in these markets.
– The Chronic Hepatitis B (CHB) EpiCast Report provides an overview of the risk factors and global trends of CHB in the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and China). It includes a 10-year epidemiological forecast for total and diagnosed prevalent cases of CHB segmented by sex and in these markets. The diagnosed prevalent cases of CHB are further segmented by hepatitis B virus (HBV) DNA level (<2000IU/mL, 2,000-20,000IU/mL, and >20,000IU/mL in the US and the 5EU, and <1000IU/mL, 1,000-10,000IU/mL, and >10,000IU/mL in Japan and China), alanine aminotransferase (ALT) level (=2 upper limit of normal [ULN] 2-5ULN and >5ULN), hepatitis e surface antigen (HBeAg) status, and the liver cirrhosis status.
– The CHB epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
Reasons to buy
The CHB EpiCast report will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global CHB market.
– Quantify patient populations in the global CHB market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CHB therapeutics in each of the markets covered.
– Identify the percentage of CHB diagnosed prevalent cases by various clinical segmentations.